Случай комбинированного лечения остеосаркомы бедренной кости

Остеосаркомы представляют собой редкие опухоли с агрессивной биологией, при подозрении на которые важно направить пациента в референсный центр, где постановка точного диагноза и выработка оптимальной тактики лечения наиболее вероятны. В отличие от саркомы Юинга остеосаркома традиционно считается резистентной к лучевой терапии, и основными компонентами полноценного лечения являются радикальное хирургическое вмешательство и химиотерапия. В представленном клиническом случае продемонстрирована эффективность комбинированного лечения остеосаркомы бедренной кости. Проведение предоперационной химиотерапии позволило оценить чувствительность опухоли к системному лечению in vivo и оптимизировать адъювантную терапию после выполнения RO-резекции, что способствовало достижению полного клинического ответа на лечение.

1. Gatta G., Capocaccia R., Botta L. et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol 2017;18(8):1022-39. DOI: 10.1016/S1470-2045(17)30445-X. Erratum in: Lancet Oncol 2017;18(8):e433.

2. Baumhoer D., Bohling T.O., Cates J.M.M. et al. Osteosarcoma. WHO Classification of Tumours Soft Tissue and Bone Tumours, 5th edn. The WHO Classification of Tumours Editorial Board (Ed), IARC Press, 2020. 403 p.

3. Mirabello L., Troisi R.J., Savage S.A. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009;115(7):1531-43. DOI: 10.1002/cncr.24121

4. Fuchs B., Pritchard D.J. Etiology of osteosarcoma. Clin Orthop Relat Res 2002;(397):40-52. DOI: 10.1097/00003086-200204000-00007

5. Grimer R.J., Cannon S.R., Taminiau A.M. et al. Osteosarcoma over the age of forty. Eur J Cancer 2003;39(2):157-63. DOI: 10.1016/s0959-8049(02)00478-1

6. Cortes-Ciriano I., Lee J.J., Xi R. et al. Comprehensive analysis of chromo-thripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet 2020;52(3):331-41. DOI: 10.1038/s41588-019-0576-7

7. Meltzer P.S., Helman L.J. New horizons in the treatment of osteosarcoma. N Engl J Med 2021;385(22):2066-76. DOI: 10.1056/NEJMra2103423

8. Zhang J., Walsh M.F., Wu G. et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med 2015;373(24):2336-46. DOI: 10.1056/NEJMoa1508054

9. Mirabello L., Zhu B., Koster R. et al. Frequency of pathogenic germline variants in cancer-susceptibility genes in patients with osteosarcoma. JAMA Oncol 2020;6(5):724-34. DOI: 10.1001/jamaoncol.2020.0197

10. Ottaviani G., Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res 2009;152:3-13. DOI: 10.1007/978-1-4419-0284-9_1

11. Gorlick R., Janeway K., Marina N. Osteosarcoma. In: Principles and practice of pediatric oncology. 7th edn. Ed. by P.A. Pizzo, D.G. Poplack. Philadelphia: Lippincott Williams and Wilkins, 2016. 882 p.

12. Buckley J.D., Pendergrass T.W., Buckley C.M. et al. Epidemiology of osteosarcoma and Ewing's sarcoma in childhood: a study of 305 cases by the Children's Cancer Group. Cancer 1998;83(7):1440-8. DOI: 10.1002/(sici)1097-0142(19981001)83:7<1440::aid-cncr23>3.0.co;2-3

13. Troisi R., Masters M.N., Joshipura K. et al. Perinatal factors, growth and development, and osteosarcoma risk. Br J Cancer 2006;95(11): 1603-7. DOI: 10.1038/sj.bjc.6603474

14. Zhang C., Morimoto L.M., de Smith A.J. et al. Genetic determinants of childhood and adult height associated with osteosarcoma risk. Cancer 2018;124(18):3742-52. DOI: 10.1002/cncr.31645

15. Inwards C.Y., Unni K.K. Classification and grading of bone sarcomas. Hematol Oncol Clin North Am 1995;9(3):545-69. PMID: 7649942.

16. Kreidieh F.Y., Moukadem H.A., El Saghir N.S. Overview, prevention and management of chemotherapy extravasation. World J Clin Oncol 2016;7(1):87-97. DOI: 10.5306/wjco.v7.i1.87

17. Rosen G., Marcove R.C., Huvos A.G. et al. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 1983;106(Suppl):55-67. DOI: 10.1007/BF00625054

18. Eilber F., Giuliano A., Eckardt J. et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987; 5(1):21-6. DOI: 10.1200/JCO.1987.5.1.21

19. Link M.P., Goorin A.M., Miser A.W. et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314(25):1600-6. DOI: 10.1056/NEJM198606193142502

20. Link M.P., Goorin A.M., Horowitz M. et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res 1991;(270):8-14. PMID: 1884563.

21. Bernthal N.M., Federman N., Eilber F.R. et al. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer 2012;118(23):5888-93. DOI: 10.1002/cncr.27651

22. Rosen G. Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience. Orthopedics 1985;8(5):659-64. DOI: 10.3928/0147-7447-19850501-19

23. Picci P., Sangiorgi L., Rougraff B.T. et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994;12(12):2699-705. DOI: 10.1200/JCO.1994.12.12.2699

24. Bielack S.S., Kempf-Bielack B., Winkler K. Osteosarcoma: relationship of response to preoperative chemotherapy and type of surgery to local recurrence. J Clin Oncol 1996;14(2):683-4. DOI: 10.1200/JCO.1996.14.2.683

25. Kawai A., Healey J.H., Boland P.J. et al. Prognostic factors for patients with sarcomas of the pelvic bones. Cancer 1998;82(5):851-9. PMID: 9486573.

26. Bacci G., Bertoni F., Longhi A. et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer 2003;97(12):3068-75. DOI: 10.1002/cncr.11456

27. Bielack S.S., Kempf-Bielack B., Delling G. et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20(3):776-90. DOI: 10.1200/JCO.2002.20.3.776

28. Hauben E.I., Weeden S., Pringle J. et al. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 2002;38(9):1218-25. DOI: 10.1016/s0959-8049(02)00037-0

29. Goorin A.M., Schwartzentruber D.J., Devidas M. et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003;21(8):1574-80. DOI: 10.1200/JCO.2003.08.165